The glucose transporter GLUT1, encoded by SLC2A1, mediates glucose transport into the brain 1,2 . GLUT1 is expressed at the BBB but not in neurons 1,2 . GLUT1 exists in two isoforms: a 55-kDa isoform in brain endothelial cells and a 45-kDa isoform in adjacent astrocyte endfoot processes 3 . The crystal structure of human GLUT1 has been recently reported 4 . Brain glucose uptake correlates with GLUT1 levels in cerebral microvessels [5] [6] [7] . GLUT1 deficiency is found in patients with epilepsy, movement disorders and cognitive impairment 8 . In mice, GLUT1 haploinsufficiency (Slc2a1 +/− ) diminishes cerebrospinal fluid (CSF) glucose levels and leads to microencephaly 9,10 . In the zebrafish, GLUT1 is required for the formation of the BBB 11 , raising the possibility of a dual role similar to that of the major facilitator family domain-containing-2a (MFSD2A) transporter, which transports essential fatty acids across the BBB into the brain and regulates BBB integrity [12] [13] [14] .
a r t I C l e S
The glucose transporter GLUT1, encoded by SLC2A1, mediates glucose transport into the brain 1, 2 . GLUT1 is expressed at the BBB but not in neurons 1, 2 . GLUT1 exists in two isoforms: a 55-kDa isoform in brain endothelial cells and a 45-kDa isoform in adjacent astrocyte endfoot processes 3 . The crystal structure of human GLUT1 has been recently reported 4 . Brain glucose uptake correlates with GLUT1 levels in cerebral microvessels [5] [6] [7] . GLUT1 deficiency is found in patients with epilepsy, movement disorders and cognitive impairment 8 . In mice, GLUT1 haploinsufficiency (Slc2a1 +/− ) diminishes cerebrospinal fluid (CSF) glucose levels and leads to microencephaly 9, 10 . In the zebrafish, GLUT1 is required for the formation of the BBB 11 , raising the possibility of a dual role similar to that of the major facilitator family domain-containing-2a (MFSD2A) transporter, which transports essential fatty acids across the BBB into the brain and regulates BBB integrity [12] [13] [14] .
Dementia due to Alzheimer's disease is characterized by progressive metabolic disturbances 15 , neurovascular dysfuction 1,2 and BBB breakdown 16 . Diminished glucose uptake in the hippocampus, parietotemporal cortex and/or posterior cingulate cortex has been shown by 2-[ 18 F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in individuals who are at genetic risk for Alzheimer's disease 17, 18 , have a positive family history 19 , and/or have mild or no cognitive impairment but go on to develop Alzheimer's disease 20, 21 . FDG-PET changes precede brain atrophy and neuronal dysfunction in humans 18, 22 and transgenic Alzheimer's disease models 23 , which may reflect reductions in BBB glucose transport 24, 25 . Reduced GLUT1 levels in cerebral microvessels were also found in Alzheimer's disease [26] [27] [28] [29] . Whether GLUT1 reductions can lead to cerebrovascular damage contributing to and/or accelerating Alzheimer's disease-like neurodegeneration remains, however, elusive.
To address this question, we crossed transgenic mice overexpressing human amyloid β-peptide (Aβ) precursor protein (APP Sw/0 ) 30 with GLUT1-deficient Slc2a1 +/− mice 9 . We also used conditional Slc2a1 loxP/loxP mice 31 to determine the effects of cell-specific GLUT1 deletions from endothelium and astrocytes on the BBB phenotype. We found that GLUT1 was necessary for the maintenance of proper brain angioarchitecture, cerebral blood flow (CBF) and BBB integrity, and that GLUT1 reductions in APP Sw/0 mice accelerated Aβ accumulation and led to progressive neuronal dysfunction, behavioral deficits, neuronal loss and neurodegeneration that developed after initial cerebrovascular changes. We also show that GLUT1 deficiency in endothelium, but not in astrocytes, initiates the BBB breakdown. Our data suggest that GLUT1 reductions at the BBB have an early pathogenic action in neuronal demise in an Alzheimer's disease-like neurodegenerative process. a r t I C l e S RESULTS Microvascular reductions and diminished cerebral blood flow and glucose uptake in GLUT1-deficient APP Sw/0 mice Immunofluorescent staining for endothelial cell-specific Lycopersicon esculentum lectin and GLUT1 ( Supplementary Fig. 1a,b) and immunoblotting of brain microvessels ( Supplementary Fig. 1c,d ) showed a ~50% reduction in GLUT1 brain endothelial levels in 6-month-old Slc2a1 +/− and Slc2a1 +/− APP Sw/0 mice as compared to their respective age-matched littermate controls ( Supplementary Fig. 1a-d) . There was no difference in GLUT1 levels between Slc2a1 +/+ APP Sw/0 and Slc2a1 +/+ mice or between Slc2a1 +/− APP Sw/0 and Slc2a1 +/− mice ( Supplementary Fig. 1a-d) .
No alterations in blood glucose were detected in Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 or Slc2a1 +/− APP Sw/0 mice ( Supplementary  Fig. 1e ). In contrast, CSF glucose and CSF-to-blood glucose ratios were reduced by 57% and 70% in 6-month-old Slc2a1 +/− and Slc2a1 +/− APP Sw/0 mice, respectively, as compared to those in Slc2a1 +/+ littermates ( Supplementary Fig. 1e,f) . CSF glucose was also reduced by ~25% in APP Sw/0 mice despite unaltered GLUT1 BBB levels.
Notably, both microvascular and CBF reductions, as found in the early disease stage in APP lines [32] [33] [34] ( see Fig. 1 below) , can diminish glucose brain uptake independently of GLUT1 expression by reducing the capillary surface area available for glucose transport and the flowdependent delivery of glucose to the brain 1,2 , respectively.
To evaluate whether reduced BBB GLUT1 expression affects brain microvascular structure, we analyzed the length of capillary networks using lectin-positive profiles (as in Supplementary Fig. 1a) . We found significant (P < 0.05) 21% and 16% reductions in capillary length in 2-week-old Slc2a1 +/− APP Sw/0 mice in somatosensory cortex and hippocampus, respectively, when compared to other genotypes. These progressed with age, as shown by greater 37% and 33% and 54% and 49% reductions in capillary length in cortex and the CA1 hippocampal subfield in 1-and 6-month-old Slc2a1 +/− APP Sw/0 mice, respectively, as compared to Slc2a1 +/+ littermate controls (Fig. 1a,b) . Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice displayed less pronounced microvascular reductions that were seen only at the later stage, 6 months of age (Fig. 1a,b) .
To find out whether brain capillary reductions determined by ex vivo histologic quantification reflect a perfusion deficit in vivo, we used (Fig. 1c,d ), suggesting that either diminished BBB GLUT1 expression or APP overexpression alone is sufficient to reduce brain capillary density, resulting in a perfusion deficit, but that when acting together they exert a strong synergistic effect, causing early loss of brain capillaries at 2 weeks of age, as seen in the Slc2a1 +/− APP Sw/0 mice. As regional brain capillary density closely correlates with regional CBF 1 , we next evaluated whether brain capillary reductions lead to diminished resting CBF. [ 14 C]Iodoantipyrine quantitative autoradiography revealed approximately 39% and 37% reductions in cortical and hippocampal blood flow in 1-month-old Slc2a1 +/− APP Sw/0 mice, respectively, when compared to other genotypes (Fig. 1e,f) . Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice did not show reductions in cortical and hippocampal blood flow at 1 month of age. At 6 months, however, both Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice developed 36% and ~30% reductions in cortical and hippocampal blood flow, respectively, that were less pronounced than the 50% and 45% reductions found in Slc2a1 +/− APP Sw/0 mice (Fig. 1e,f) . Hemodynamic and physiologic parameters that may influence CBF, including mean arterial blood pressure, respiratory rate, heart rate, blood pH, and arterial partial pressure of CO 2 and O 2 , did not differ among Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 or Slc2a1 +/− APP Sw/0 mice on the same mixed genetic background ( Supplementary Fig. 2a-i) .
Laser Doppler flowmetry studying functional hyperemic responses to whisker-barrel vibrissal stimulation revealed early and significantly greater age-dependent reductions in CBF responses in 1-month-old Slc2a1 +/− APP Sw/0 mice as compared to Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice, both of which developed less pronounced changes that began at 6 months of age (Fig. 1g) . No changes in CBF responses were observed in Slc2a1 +/+ littermates. Collectively, these data show that both resting CBF and CBF responses are impaired early in animals with diminished GLUT1 function in the presence of the APP transgene and are further worsened with age as compared to those in either GLUT1-deficient or APP Sw/0 mice alone.
Autoradiography analysis with 2-[ 14 C]deoxyglucose (2-DG) indicated 2-DG uptake diminished by 32-36% and 26-30% in the cortex and hippocampus, respectively (Fig. 1h) , as well as in other brain regions (Supplementary Table 1) , at an early stage in Slc2a1 +/− and Slc2a1 +/− APP Sw/0 mice. This suggests that reduced glucose BBB transport leads to reduced brain glucose.
GLUT1 deficiency leads to early BBB breakdown GLUT1 reductions result in BBB breakdown in the developing zebrafish 11 and in vitro BBB models 35 . To examine whether similar relationship exists in the adult mammalian brain, we next sought to characterize BBB integrity through leakage of endogenous plasma proteins, such as fibrin and immunoglobulin G (IgG), in Slc2a1 +/− mice. Young, 2-week-old Slc2a1 +/− mice demonstrated gross microvascular leakage and extravascular accumulation of circulating fibrin and IgG, with 10-fold and 11-fold increases, respectively, as compared to those in control age-matched Slc2a1 +/+ littermates (Fig. 2a-c) . Much smaller but statistically significant 1.5-and 2-fold increases in extravascular fibrin and IgG, respectively, were observed in 2-weekold Slc2a1 +/+ APP Sw/0 mice as compared to age-matched Slc2a1 +/+ controls (Fig. 2a-c) , consistent with previous findings demonstrating early cerebral microvascular changes and BBB breakdown in APP Sw/0 mice before significant Aβ accumulation [36] [37] [38] . By contrast, there were substantial, approximately 18-and 20-fold increases in parenchymal accumulation of plasma-derived fibrin and IgG, respectively, in Slc2a1 +/− APP Sw/0 mice when compared to Slc2a1 +/+ littermates. These values were also 75% and 41% higher than those in Slc2a1 +/− littermates ( Fig. 2a-c) . Western blot analysis of fibrin and IgG in vascular-depleted brain homogenates confirmed the immunostaining results (Fig. 2d-f) . More progressive fibrin and IgG leakages were found in 6-month-old mice when compared to 2-week-old mice (Supplementary Fig. 3 ), but the trend of changes observed between different genotypes remained the same as in 2-week-old mice. These data suggest that GLUT1 is required for maintenance of BBB integrity in mice and that reduction in GLUT1 expression may accelerate and augment changes in vascular permeability seen with increased Aβ, such as in APP Sw/0 mice 38 .
We next studied whether the expression of the BBB tight junction proteins underlying the barrier properties of brain endothelium is altered by GLUT1 deficiency in the mammalian brain, as it is in the lower vertebrate brain lacking GLUT1 (ref. 11). Immunostaining for the tight junction proteins occludin or zonula occludens-1 (ZO-1), each combined with lectin staining, indicated early and significant reductions in both tight junction proteins, by approximately 40% and 50%, respectively, in Slc2a1 +/− mice when compared to agematched Slc2a1 +/+ littermates ( Fig. 2g-i) . We also found a moderate, ~20% reduction in occludin length, but not ZO-1 length, in Slc2a1 +/+ APP Sw/0 mice as compared to age-matched Slc2a1 +/+ controls (Fig. 2g,h ), which may explain the increased BBB leakage in APP Sw/0 mice ( Fig. 2a-f) . Slc2a1 +/− APP Sw/0 mice had significantly greater losses of occludin and ZO-1 when compared to Slc2a1 +/+ APP Sw/0 mice, suggesting that reductions in GLUT1 in the setting of an abundance of Aβ results in greater tight junctional reductions and permeability deficits. The reductions in tight junction protein expression in different mouse lines correlated well with increased BBB permeability, as illustrated by negative correlations between the extravascular fibrin and IgG deposits and the occludin capillary length (Fig. 2j,k) , respectively, when compared to those in Slc2a1 +/+ littermate controls. Immunoblotting of isolated microvessels confirmed that the greatest reductions in occludin, ZO-1 and claudin-5 at 2 weeks of age were in Slc2a1 +/− APP Sw/0 mice (Fig. 2l,m) .
GLUT1 deficiency leads to accelerated cerebral b-amyloidosis
The BBB is a critical site of transport exchanges regulating brain Aβ 1,2 . To investigate whether diminished BBB GLUT1 expression influences progression of CNS β-amyloidosis, we analyzed Aβ pathology. At 16 months of age, Aβ 40 and Aβ 42 were respectively increased by 73% and 48% in the cortex and 89% and 53% in the hippocampus of Slc2a1 +/− APP Sw/0 mice when compared to age-matched littermate controls (Fig. 3a,b ). Also at 6 months of age, Aβ 40 and Aβ 42 were respectively increased by 28% and 95% in the cortex and 51% and 80% in the hippocampus of Slc2a1 +/− APP Sw/0 mice when compared to littermate controls (Fig. 3a,b ) At 1 month of age, however, Aβ levels in the cortex and hippocampus of Slc2a1 +/− APP Sw/0 mice were not elevated (Fig. 3a,b) , suggesting that early reductions in capillary density in these mice (Fig. 1a,b) are not related to Aβ, but could be due to either early postnatal and/or developmental synergistic effects of GLUT1 deficiency and APP overexpression. Aβ immunostaining confirmed 53% and 62% increases in cortical and hippocampal Aβ load, respectively, in 16-month-old Slc2a1 +/− APP Sw/0 as compared to Slc2a1 +/+ APP Sw/0 mice (Fig. 3c,d ), suggesting that GLUT1 deficiency accelerates and exacerbates cerebral β-amyloidosis in APP Sw/0 mice. npg a r t I C l e S To investigate the mechanism(s) by which GLUT1 BBB transporter may influence Aβ homeostasis, we studied whether GLUT1 deficiency alters brain capillary levels of low-density lipoprotein receptorrelated protein 1 (LRP1), a key Aβ clearance transporter at the BBB 1,2 .
Immunoblotting revealed a significant 47% reduction in brain capillary LRP1 in 16-month-old Slc2a1 +/+ APP Sw/0 mice as compared to age-matched Slc2a1 +/+ littermates, consistent with a previous report 39 , and a more severe 75% reduction in 16-month-old Slc2a1 +/− APP Sw/0 mice as compared to age-matched Slc2a1 +/+ littermates (Fig. 3e) . Surprisingly, brain capillary LRP1 levels were also reduced by 26% in 16-month-old Slc2a1 +/− mice as compared to Slc2a1 +/+ age-matched littermates (Fig. 3e) . In agreement with these findings, an in vivo hippocampal clearance assay for human Aβ 40 indicated an Aβ 40 retention increased by 59% in Slc2a1 +/− APP Sw/0 mice when compared to Slc2a1 +/+ APP Sw/0 mice, in the absence of altered clearance of the metabolically inert molecule inulin (Fig. 3f) . In agreement with the observed LRP1 BBB reductions and increased Aβ 40 retention, we found a 67% reduction in BBB clearance of Aβ without changes in Aβ interstitial fluid bulk flow (Fig. 3g) . Notably, APP, soluble amyloid precursor protein-β, β-secretase, neprilysin and insulin-degrading enzyme levels were not altered in 16-month-old Slc2a1 +/− APP Sw/0 mice as compared to Slc2a1 +/+ APP Sw/0 littermates, indicating that enhanced APP production and/or processing or reduced Aβ enzymatic degradation do not contribute to exacerbations in β-amyloidosis in Slc2a1 +/− APP Sw/0 mice ( Supplementary Fig. 4a-g ). Together, these data are consistent with a faulty LRP1-dependent Aβ clearance at the BBB.
To confirm that diminished LRP1-dependent Aβ clearance is critical for Aβ accumulation in Slc2a1 +/− APP Sw/0 mice, we re-expressed npg a r t I C l e S a human LRP1 minigene (mLRP1) 40 in the hippocampus of Slc2a1 +/− APP Sw/0 mice using adenovirally mediated transfer (Ad.mLRP1). This led to robust expression of the LRP1 minigene in the hippocampus, particularly within blood vessels of Slc2a1 +/− APP Sw/0 mice ( Supplementary Fig. 5a -c) and resulted in significant reductions in Aβ load and Aβ 40 and Aβ 42 levels, by 45%, 35% and 22%, respectively, as compared to those in the contralateral control hippocampus injected with the control empty vector (Fig. 3h-j) . These data indicate that reduced microvascular LRP1 levels contribute to diminished Aβ clearance in GLUT1-deficient APP Sw/0 mice. Additionally, reductions in brain capillary surface area and resting CBF may also diminish Aβ clearance. To confirm that GLUT1 regulates LRP1-dependent Aβ clearance at the BBB in vivo, we performed a rescue experiment with GLUT1, re-expressing GLUT1 in the hippocampus of Slc2a1 +/− APP Sw/0 mice using adenovirally mediated Ad.Slc2a1 transfer. In comparison to expression in the hippocampus injected with the control empty vector, Ad.Slc2a1 increased the expression of both GLUT1 and LRP1 in brain microvessels (Supplementary Fig. 5d-g ), which in turn reduced the Aβ load, Aβ 40 and Aβ42 levels by 37%, 45% and 33%, respectively ( Fig. 3k-m) . Collectively, these data imply that re-expression of GLUT1 in Slc2a1 +/− APP Sw/0 mice slows development of Aβ pathology by increasing cerebrovascular LRP1.
To better understand the link between GLUT1 and LRP1, we next performed a series of experiments using primary mouse brain endothelial cells (BECs). Consistent with a recent report showing that GLUT1 levels in brain microvessels in different mouse strains correlate closely with LRP1 levels-that is, the lower the GLUT1 levels, the lower the LRP1 levels 41 -and our findings of reduced LRP1 in brain microvessels of Slc2a1 +/− mice (Fig. 3e) , we found that GLUT1 inhibition with a short interfering RNA targeting Slc2a1 (si.Slc2a1) led to transcriptional LRP1 suppression in Slc2a1 +/+ BECs, whereas Ad.Slc2a1 adenovirally mediated re-expression of GLUT1 in Slc2a1 +/− BECs increased LRP1 (Supplementary Fig. 6a-c) . Silencing LRP1 failed to decrease GLUT1 (Supplementary Fig. 6d ), suggesting that changes in GLUT1 expression influence LRP1 expression.
In search of a possible molecular mechanism, we studied whether the sterol regulatory element binding protein 2 (SREBP2)-the only known transcriptional suppressor of LRP1 (refs. 42,43) previously shown to inhibit LRP1 in brain vascular cells in Alzheimer's disease and disease models 42 -is involved in mediating GLUT1 effects. si.Slc2a1-mediated GLUT1 inhibition increased SREBP2 levels and suppressed LRP1 levels in Slc2a1 +/+ BECs, whereas inhibition of GLUT1 in the presence of silenced SREBP2 expression (si.Srebp2) failed to suppress LRP1 (Supplementary Fig. 6e-h) . SREBP2 levels were increased in Slc2a1 +/− BECs when compared to Slc2a1 +/+ npg a r t I C l e S BECs, which correlated with LRP1 reduction (Supplementary Fig. 6i-k) . Together, these findings indicate that SREBP2 is critical for LRP1 suppression in BECs.
Neuronal dysfunction and cognitive impairment in Slc2a1 +/− APP Sw/0 mice We used in vivo voltage-sensitive dye (VSD) imaging to determine evoked membrane potential responses with millisecond temporal resolution immediately following hindlimb mechanical stimulation 44 . In Slc2a1 +/+ mice, hindlimb stimulation evoked a robust, transient depolarization (<100 ms) originating in the contralateral hindlimb somatosensory cortex, which subsequently propagated to adjacent motor and forelimb somatosensory cortices before returning to baseline values (Fig. 4a) . At 2 weeks of age, evoked cortical depolarization displayed no abnormalities in peak amplitude of response, as measured by peak change in fluorescence normalized to baseline fluorescence (peak ∆F/F 0 ) and response latency in Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 or Slc2a1 +/− APP Sw/0 mice (Fig. 4b,e,f) . By contrast, reductions in evoked hindlimb cortical response amplitude and prolongation of response latency were noted in Slc2a1 +/− APP Sw/0 mice, but not in Slc2a1 +/− or Slc2a1 +/+ APP Sw/0 mice, beginning at 1 month of age (Fig. 4a,c-f) . By 6 months, cortical responses in Slc2a1 +/− APP Sw/0 mice were substantially reduced, with severely prolonged response latency (Fig. 4a,d-f) . We also found more moderate reductions in cortical activity in Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice beginning at 6 month of age (Fig. 4a,d-f ). These data demonstrate that the vascular changes readily detectable at 2 weeks of age in Slc2a1 +/− APP Sw/0 mice (Figs. 1a,b and 2 ) preceded neuronal dysfunction. Similar, BBB breakdown in Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice also preceded diminished evoked membrane potential responses, although neuronal dysfunction in Slc2a1 +/− and Slc2a1 +/+ APP Sw/0 mice developed slower than in Slc2a1 +/− APP Sw/0 mice. Next we sought to evaluate function of neuronal circuitries underlying hippocampal learning and spatial memory through the assessment of novel object location (Fig. 5a ) and novel object recognition memory (Fig. 5b) . At 1 month of age, no impairment in novel object location or recognition memory was detected in 1-month-old Slc2a1 +/− APP Sw/0 mice (Fig. 5a,b) . At 6 months of age, however, Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice all showed significant impairment in novel object location and recognition memory (Fig. 5a,b) . As observed with VSD imaging, novel object location and recognition memory was most severely affected in Slc2a1 +/− APP Sw/0 mice (Fig. 5a,b) . Assessment of nest construction confirmed the onset of behavioral impairment Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and the more severely affected Slc2a1 +/− APP Sw/0 mice at 6 months but not at 1 month of age (Fig. 5c) . Behavioral deficits were not the result of reduced locomotor activity (Fig. 5d) . Golgi-Cox histological analysis revealed graded dendritic spine reductions in the dentate gyrus in 6-month-old Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice (Fig. 5e,f) , which closely correlated with genotype-dependent impairments in hippocampal function.
GLUT1 deficiency results in neurodegenerative changes in APP Sw/0 mice Quantification of SMI-311-positive unphosphorylated neurofilament in the hindlimb somatosensory cortex and CA1 hippocampal subfield 44 revealed no significant differences in 1-month-old Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice as compared to agematched control Slc2a1 +/+ littermates, confirming that vascular dysfunction preceded detectable neuronal structural changes (Fig. 6a,b) . At 6 months of age, significant 18% and 22% reductions in hippocampal and cortical SMI-311 positive neurofilaments were noted in Slc2a1 +/− APP Sw/0 mice, respectively, as compared to other genotypes (Fig. 6a,b) . Significant 15% and 13% reductions in neurofilament density (P < 0.05) were detected in the cortex and hippocampus in 16-month-old Slc2a1 +/− mice, but not in Slc2a1 +/+ APP Sw/0 or a r t I C l e S age-matched littermate controls. This compares to more pronounced, 23% and 28% respective reductions in age-matched Slc2a1 +/− APP Sw/0 mice (Fig. 6a,b) .
To evaluate neuronal loss, we next quantified neuron-specific nuclear protein A60 (NeuN)-positive cells in the cortex and hippocampus of Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice as compared to age-matched control Slc2a1 +/+ littermates . This quantification revealed significant (P < 0.05) 15% and 31% in hippocampal and 16% and 25% in cortical NeuN-positive cells in 6-and 16-month-old Slc2a1 +/− APP Sw/0 mice, respectively (Fig. 6c,d) . No changes were observed in other genotypes at 6 months of age. Significant (P < 0.05) 13% and 14% reductions in NeuN-positive cells were detected, however, in the CA1 hippocampal subfield and somatosensory cortex, respectively, in 16-month-old Slc2a1 +/− mice (Fig. 6c,d ). Consistent with a previous report 45 , we did not find neuronal loss in Slc2a1 +/+ APP Sw/0 mice at any time point analyzed (Fig. 6c,d) .
We also checked for gross alterations in brain architecture through measurement of mean cortical diameter, an index of brain size. This analysis demonstrated 4% and more severe 7% reductions in 6-month-old Slc2a1 +/− and Slc2a1 +/− APP Sw/0 mice, respectively, but no significant alterations in brain size in Slc2a1 +/+ APP Sw/0 mice (Fig. 6e,f) .
GLUT1 deficiency in endothelium initiates vascular BBB changes
Brain microvessels from Slc2a1 +/+ mice express the 55-kDa GLUT1 endothelial isoform 3 , whereas capillary-depleted brain homogenates containing astrocytes and neurons but not microvessels (as shown by multiple cell-specific markers on immunoblots) express the 45-kDa GLUT1 astrocytic isoform 3 at very low levels ( Supplementary  Fig. 7a-c) . When compared to the 55 kDa isoform, the levels of the 45 kDa GLUT1 isoform were approximately 26-fold lower. In Slc2a1 +/− mice as compared to Slc2a1 +/+ controls, we found >50% and 40% losses of the 55-and 45-kDa GLUT1, respectively ( Supplementary  Fig. 7d,e) . Moreover, in the capillary-depleted brains of Slc2a1 +/− mice as compared to Slc2a1 +/+ mice, we detected a 2-fold increase in GLUT2, a glucose transporter that is expressed in astrocytes 3, 46 , and a 2.6-fold increase in GLUT3, a glucose transporter that is expressed in neurons 46, 47 , suggesting metabolic adaptations in different cell types in the presence of GLUT1 deficiency (Supplementary Fig. 7f,g ). , n = 3-6 mice per group; *P < 0.05 or **P < 0.01. (e,f) Representative low-magnification bright-field microscopy of mouse brains (e) and quantification of maximal brain diameter (f) in 6-month-old Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice. Scale bar, 5 mm. Mean ± s.e.m., n = 5 or 6 mice per group; *P < 0.05 or **P < 0.01. npg a r t I C l e S Using primary mouse BECs and astrocytes from Slc2a1 +/+ mice, we found that the 55-kDa GLUT1 in BECs was expressed at significantly higher levels by approximately 20-fold, as compared to the 45-kDa GLUT1 in astrocytes (Supplementary Fig. 7h ) and that GLUT1 haploinsufficiency led to a 60% loss of GLUT1 from BECs and >40% loss of GLUT1 from astrocytes, and a 3.5-fold increase in GLUT2 in astrocytes (Supplementary Fig. 7i,j) . Thus, global GLUT1 deficiency leads to a critical loss of glucose transporters from endothelium that likely has a major effect on the vascular phenotype in Slc2a1 +/− mice. In contrast, astrocytes express substantially less GLUT1 at baseline and, during GLUT1 global deficiency, maintain less significant loss of glucose transporters, as indicated by the smaller loss of GLUT1 and a compensatory increase in GLUT2.
We then took advantage of conditional Slc2a1 loxP/loxP mice 31 and generated Slc2a1 loxP/+ ;Tie2-Cre +/0 and Slc2a1 loxP/+ ;GFAP-Cre +/0 mice, with partial GLUT1 deletions from endothelium and astrocytes, respectively, to determine their respective effects on the BBB integrity that we found to be compromised early in Slc2a1 +/− mice, at 2 weeks of age (Fig. 2) . As expected, we found diminished levels of GLUT1 in endothelium in Slc2a1 loxP/+ ;Tie2-Cre +/0 mice by double immunostaining for GLUT1 and lectin-positive endothelial profiles (>40%) and immunoblotting for 55-kDa endothelial isoform in isolated brain microvessels (~45%), but no change in the astrocyteassociated 45-kDa isoform in capillary-depleted brains ( Supplementary  Fig. 8a-d) . In contrast, Slc2a1 loxP/+ ;GFAP-Cre +/0 mice did not have loss of GLUT1 from endothelium, confirming that GLUT1 deletion from astrocytes does not affect function of endothelial GLUT1. In Slc2a1 loxP/+ ;GFAP-Cre +/0 mice, GLUT1 was undetectable in brain parenchyma by immunostaining, as reported 3 , but there was >50% loss of the 45-kDa isoform in the astrocyte-containing capillarydepleted brains (Supplementary Fig. 8d) .
We next found BBB breakdown in endothelial GLUT1-deficient Slc2a1 loxP/+ ;Tie2-Cre +/0 mice, but not in astrocyte GLUT1-deficient Slc2a1 loxP/+ ;GFAP-Cre +/0 mice, as shown by 10-and 15-fold greater extravascular accumulation of fibrin and IgG in brain parenchyma (Fig. 7a-c) , and 45% and 47% reductions in the length of the BBB tight junction proteins occludin and ZO-1, respectively (Fig. 7d-f npg a r t I C l e S controls. In contrast, GLUT1 deficiency in astrocytes in Slc2a1 loxP/+ ; GFAP-Cre +/0 mice did not result in BBB breakdown. A decrease in the occludin length in Slc2a1 loxP/+ ;Tie2-Cre +/0 mice correlated with increased BBB breakdown to fibrin and IgG (Fig. 7g,h Fig. 9a ). RBCs in Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice had normal shape (Supplementary Fig. 9b ) and normal mechanical properties under shear stress conditions (1.5-50 pascal) ( Supplementary  Fig. 9c ). Slc2a1 +/+ , Slc2a1 +/− , Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice all had normal hematological parameters, such as the amount of hemoglobin, average RBC size, the amount of hemoglobin per RBC, the amount of hemoglobin relative to the size of the cell, and red cell distribution width, as well as normal saturation of oxygen in hemoglobin and normal partial pressure of oxygen at half saturation, a measure of oxygen dissociation ( Supplementary Fig. 9d-l) . These data suggest that peripheral changes in RBCs do not contribute appreciably to the observed effects in the brain.
DISCUSSION
We show that GLUT1, in addition to its well-known role in transporting glucose into the brain 1,2 , is necessary for the maintenance of proper brain capillary networks, blood flow and BBB integrity, as well as neuronal function and structure ( Supplementary  Fig. 10 ). Capillary degeneration and BBB breakdown occurred early in Alzheimer's disease model mice with GLUT1 deficiency (Slc2a1 +/− APP Sw/0 ), at 2 weeks of age, and were associated with reduced brain perfusion and diminished glucose uptake into the brain, whereas neuronal dysfunction, behavioral deficits, elevated Aβ levels and behavioral and neurodegenerative changes developed later, by 6 months of age. GLUT1 deficiency in endothelium, but not astrocytes, initiates the vascular phenotype with BBB breakdown. Besides reductions in the tight junction proteins, early metabolic changes in the endothelium due to reduced glucose uptake might contribute to endothelial cell injury and BBB breakdown. Loss of GLUT1 from brain endothelium generates multiple parallel pathogenic mechanisms in the cerebral microcirculation, which can contribute to the observed neuronal dysfunction and neurodegeneration. Each of these vascular insults alone-the BBB breakdown, diminished BBB glucose transport, CBF reductions, capillary degeneration, neurovascular uncoupling and impaired Aβ BBB clearance-may be independently neuronal toxic, but their synergy is likely to amplify the overall pathogenic effects of GLUT1 deficiency.
Metabolic stress due to chronically reduced glucose levels in brain, if not compensated, may lead to neuronal and glial hypometabolism and oxidative stress, which can contribute to neurotoxicity 48 . Additionally, shifts in metabolism can take place in different cell types within the neurovascular unit, and at different stages during limited glucose availability. The metabolic pathways through which BBB GLUT1 reductions influence brain metabolism, including endothelial glucose metabolism, the astrocyte lactate shuttle and/or oxidative metabolism, and neuronal supply, are unknown and likely to represent an important focus for future studies.
When combined with APP overexpression, GLUT1 reduction results in early neurodegeneration marked by the retraction of neurites, neuronal loss and substantial behavioral deficits at 6 months of age that are not seen in APP Sw/0 mice, as shown in the present and earlier reports 45, 49 . GLUT1 deficiency leads to reductions in Aβ clearance and accelerates Aβ pathology via reduced expression of LRP1 in the microvasculature. Notably, these changes are reversible, as demonstrated in the GLUT1 and LRP1 rescue experiments in the hippocampus. Therefore, neuronal loss in Slc2a1 +/− APP Sw/0 mice likely reflects synergistic effects of GLUT1-mediated vascular injury, diminished neuronal glucose delivery and greater accumulation of Aβ neurotoxic species at the neuronal interface.
Our data using GLUT1-deficient mice with an early embryonic loss of GLUT1 suggest that GLUT1 may fulfill an important regulatory function in the microcirculation and Aβ clearance in the adult and aging brain. Future studies using mouse models with inducible GLUT1 loss from endothelium might address whether there is a difference in the CNS response to an early embryonic GLUT1 loss as compared to a later GLUT1 loss from brain. Interestingly, adult patients with GLUT1 deficiency syndrome 50 do not show clinical evidence of Alzheimer's disease. Whether GLUT1 deficiency can accelerate cognitive decline during aging in humans remains, however, to be seen. The present data suggest that GLUT1 deficiency can contribute to a disease process acting in tandem with Aβ to initiate and/or amplify vascular damage and Aβ accumulation.
The two-hit vascular hypothesis of Alzheimer's disease states that early vascular injury leads to BBB compromise and perfusion stress, which can initiate Aβ-independent and Aβ-dependent mechanisms of neurotoxicity 2 . Here, we show that GLUT1 transporter at the BBB influences both Aβ-independent and Aβ-dependent neuronal injury. The molecular mechanisms governing GLUT1 reductions in Alzheimer's disease and whether these may be pharmacologically targeted to restore GLUT1 expression remain unknown. Nevertheless, our data suggest that GLUT1 is an important therapeutic target for Alzheimer's disease-related neurovascular dysfunction and neurodegeneration.
METHODS
Methods and any associated references are available in the online version of the paper. a r t I C l e S Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html.
analyzed in six nonadjacent sections (~140 µm apart). Three to six animals per group were analyzed.
SMI-311-positive neuritic density. SMI 311 labels unphosphorylated neurofilament in the soma, axons and dendrites 44, 51 . The SMI-311-positive area was determined using the ImageJ area measurement tool. Three randomly selected fields from the cortex and two randomly selected fields from the stratum radiatum region of the CA1 hippocampal region were analyzed in six nonadjacent sections (~140 µm apart). Three to four animals per group were analyzed.
Quantitative protein analysis. Immunoblotting analysis. Brain capillaries were isolated as we described 51, 54, 55 . Capillary-depleted brain homogenates were prepared as we described using dextran density gradient centrifugation to separate microvessels from total brain homogenenates 33, 49 . Samples were subjected to SDS-PAGE and transferred to a nitrocellulose membrane. Densitometry analysis was performed using an AlphaImager 2200 and AlphaEase FC software (Alpha Innotech Corporation).
Human Aβ measurement. We use ELISA analysis as previously described 49 . Three to six mice were analyzed per group.
Bright-field microscopy analysis. Golgi-Cox staining. Golgi-Cox staining was performed as we described 51, 56 . The outer molecular layer of the dentate gyrus was imaged with a 63× objective using an Olympus AX70 bright-field microscope (Olympus America). Spines (>0.2 µm) were counted using the NIH ImageJ cell counter analysis tool and expressed as number per 10 µm dendrite. Values from 100 dendrites were averaged per section and three sections in each region were analyzed per animal. Four animals per group were analyzed. neuronal function. Voltage-sensitive dye (VSD) imaging and analysis. In vivo VSD imaging was performed as described 44 . Mice were anesthetized intraperitoneally with 1,250 mg/kg urethane. A cranial window was placed over the somatosensory cortex. The dye RH-1692 VSD (Optical Imaging) dissolved in artificial cerebrospinal fluid was applied to the exposed somatosensory cortex for 60 min. Images were collected using a 12-bit Pixelfly CCD camera coupled to CamWare 3.0 image acquisition software. RH-1692 was excited using a 627-nm red LED light source and imaged using a custom-built Olympus 2x epifluorescence microscope. Images were collected for 500 ms before and after a mechanical deflection of the hind limb 44 . The responses were averaged from 10-20 trials per animal. The change in fluorescent VSD signal was calculated as a percentage change by dividing the signal intensity after stimulation by the average intensity before stimulation (∆F/F 0 ). The signal intensity was quantified by placing a circular region area of interest over the hind limb region of somatosensory cortex using NIH Image software. The images were subsequently pseudocolored using a custom-designed NIH ImageJ macro. Three or four animals were analyzed per group. Brain clearance. Aβ 40 was iodinated with 125 I and purified as we described 57 . Intrahippocampal clearance of radiolabeled Aβ 40 in 16-month-old Slc2a1 +/+ APP Sw/0 and Slc2a1 +/− APP Sw/0 mice was studied as we described 39, 58 . The inert molecule [ 14 C]inulin was co-injected to assess nonspecific elimination via brain interstitial fluid flow (ISF). Briefly, a stainless steel guide cannula was implanted stereotactically into the hippocampus of anesthetized mice (0.5 mg/kg ketamine and 5 mg/kg xylazine i.p.). Animals were allowed to recover after surgery before clearance studies. Tracer fluid (0.5 µl) containing [ 125 I]Aβ 40 and [ 14 C]inulin was injected into brain ISF over 5 min via an ultramicropump with a micro4-controller (World Precision Instruments, Sarasota, FL). Brain was sampled 30 min after tracer injection and prepared for 125 I TCA-precipitable and 14 C radioactivity analysis 39, 58 . In all calculations, the d. In vivo transduction in the hippocampus. Mice were anesthetized (0.5 mg/kg ketamine and 5 mg/kg xylazine i.p.). A single stainless steel cannula was implanted into the hippocampus for clearance studies. In a subset of mice, an additional stainless steel cannula was placed on the contralateral side to allow ipsilateral versus contralateral comparisons between control and mLRP1 viral constructs. Mice were reanesthetized the following day and injected slowly (0.1 µL/min by MicroSyringe pump, World Precision Instruments) with a viral suspension containing 1 × 10 9 p.f.u. of empty virus called Ad.Ctrl or Ad.mLRP1, an adenoviral construct containing an LRP1 minigene (comprising the entire cytoplasmic signaling/internalization domain and Aβ binding domain of LRP1) 40, 44 . Polyl-lysine (100 molecules per viral particle) was used to enhance transduction. The murine Slc2a1 expression adenovirus Ad.Slc2a1 was produced by SignaGen Laboratories. The mouse Slc2a1 gene was under control of a CAG promoter. In vivo transduction in the hippocampus with Ad.Slc2a1 or control empty vector was performed as above. The mice were allowed to recover for 5 d and were then either used for immunostaining/immunoblotting analysis or used for clearance studies performed as described above.
